Archives: 6/2007

13452fit Ins and Outs

  • Ultra Deep Sequencing Identifies HIV Drug Resistance at Early Stage
    [Yale]
  • New Orphan: FDA approves Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension
    [FDA]
  • F.D.A. Tracked Poisoned Drugs, but Trail Went Cold in China
    [NY Times]
  • Animal Research Uncovers Another Mechanism of Cholesterol Lowering Ezetimibe (Zetia) Drug
    [Wake Forest University School of Medicine]
  • New findings challenge established views about human genome
    [European Molecular Biology Laboratory]
  • Our Microbial Menagerie — New genomic technologies allow us to study the thriving but mysterious populations of microorganisms in our bodies, providing important insights into obesity and other health problems.
    [MIT Tech Review]
  • Gene responsible for common hearing loss identified for first time
    [European Society of Human Genetics]
  • Researchers Discover a Small Set of Cancer Stem Cells That Are Similar To Normal Stem Cells and Appear To Thwart Anti-Cancer Agents
    [University of Pittsburgh School of Medicine ]
  • FDA Releases Human Tissue Task Force Report
    [FDA]
  • Phytomedics, developer of an arthritis drug based on extracts from the Chinese Thunder God Vine, nabs $9 million in Series B funding.
    [Red Herring]
  • To keep fit in space, train like an athlete
    [National Space Biomedical Research Institute]
  • Study: Prehistoric Man Had Sex for Fun
    [Fox News]
  • 523521vi1 EndoSite 3Di Digital Vision System Now Used for Thoracic and Neuro Cases
    EndoSite 3Di Digital Vision System has been used for the first time to perform videothoracoscopic surgery. The operation (parietal pleurectomy, a sublobar resection, and a chemical pleurodesis) was performed at Regional Oncologic Hospital in Rionero in Vulture, PZ, Italy, according to Viking Systems, Inc., the manufacturer of this laparoscopic visualization assistance device. 523521vi2 EndoSite 3Di Digital Vision System Now Used for Thoracic and Neuro Cases When we first reported about the system in 2005, it was only used for laparoscopic gynecologic, urologic and general surgical cases. In addition to the videothoracoscopic case, the system was recently used for a minimally invasive pediatric neurosurgical case (a repair of craniosynostosis).
    To learn about the system, go to our previous post, or Viking Systems home page.
    Press release: First Minimally Invasive Thoracic Surgeries Using Viking Systems’ 3Di Vision System Performed at Regional Oncologic Hospital in Rionero in Vulture, PZ, Italy …
    Press release: Infant is First to Undergo Minimally Invasive Neurosurgery Procedure With Viking Systems’ 3D Surgical Vision System …
    (hat tip: MTB Europe)

    9051 russia Ins and Outs

  • Hybrid Gold-Dendrimer Nanoparticles Target and Image Tumors
    [NCI's Alliance for Nanotechnology in Cancer]
  • Phase I Clinical Trial Shows Nanoparticle-Enabled Thermal Therapy Safe for Treating Cancer
    [NCI's Alliance for Nanotechnology in Cancer]
  • Growing Mammalian Cells on Nanowires Provides Novel View of Cell Activity
    [NCI's Alliance for Nanotechnology in Cancer]
  • Nanoparticles Image siRNA Delivery Into Tumors
    [NCI's Alliance for Nanotechnology in Cancer]
  • J.&.J. Says It Is Cleared to Offer New Products
    [NYT/Reuters]
  • Fathers have ‘sympathy pregnancies’, study shows
    [St George's, University of London]
  • Researchers Agree with Oprah: Drunkenness Comes Faster After Gastric Surgery
    [Forbes/HealthDay]
  • ‘Aftershave drink’ kills Russians
    [BBC News]
  • eyetracker Retinal Stabilization, Biorobotics and the Science of VisionBBC News is reporting that scientists under Dr. Michele Rucci at Boston University developed a technique to stabilize eye movements. What they uncovered is that tiny, involuntary flickering movements of the eyes seem to allow our vision to get sharper. Their research is published in the latest issue of Nature.

    Professor Michele Rucci and colleagues used a new technique for counteracting the visual effects of the eye movements to test their effects on vision.
    They were able to stop the effects of the movements for short periods of time, so that vision did not start to fade.
    They found that, without the motion, people in the study were less able to perceive fine details in images.

    12123mrt Retinal Stabilization, Biorobotics and the Science of VisionThe group’s retinal stabilization experiments were carried on an instrument called EyeRIS, (Eye movement Real-time Integrated System), an “in-house developed system for gaze-contingent display control. This hardware and software system allows flexible real-time modification of the stimulus according to subject’s eye movements with refresh rates up to 200Hz.” We found details about the EyeRIS on this project page.
    Active Perception Laboratory, where the instrument was developed, also has a range of biorobotic machines that are part of an “ongoing effort of coupling computational models of the brain with behaving automata.”
    See more machines at biorobotics page.
    More about psyhophysical experiments at the Active Perception Laboratory…
    BBC News article: Eye flickers key for fine detail …

    numberonesm1 Were Number OneeDrugSearch.com has compiled a list of the top 100 medical blogs. Their purpose, in their words:

    Our goal is to provide both bloggers and blog readers interested in all aspects of healthcare with a simple way to find the most influential blogs. We rank each blog’s influence based on a multimetric algorithm… Ranks are based on a combination of four source.

    They add up a site’s Google Pagerank, Bloglines subscriber rank, Technorati authority rank, and their own homegrown measure of quality and frequency of posting.
    Let’s just say we’re not bowled over by the rigor of this system — too many important blogs are missing, some defunct blogs are included, and a closer look at individual numbers just makes us scratch our heads…
    Nor do we think ranking blog influence is as useful or necessary as, say, ranking hospitals or colleges. The Medical blogosphere is a growing community of vital, insightful voices. We have an opportunity to fundamentally change the way health information is communicated. Medical blogs should be surveyed, scrutinized, categorized… but not ranked.
    But… If someone is going to rank them… We’re glad we’re at the top.

    66016red How to Barter a KidneyHere’s a fantastic idea. Computer scientists at Carnegie Mellon University thought that two-, three- or four-way barter exchanges might improve kidney donor/recipient matching. Lo and behold, they were right! A recently presented paper “Clearing Algorithms for Barter Exchange Markets: Enabling Nationwide Kidney Exchanges” has proven just that:

    The matching algorithm makes it possible to create matches for three- and four-way exchanges–that is, three or four donors matched to three or four recipients–as well as two-way exchanges. It is the first that is scalable so it can be used for a national pool of donors and recipients, said Tuomas Sandholm, professor of computer science.
    A paper detailing the algorithm, developed by Sandholm, Computer Science Professor Avrim Blum and graduate assistant David J. Abraham, will be presented Friday at the Association for Computing Machinery’s Conference on Electronic Commerce in San Diego.
    The Alliance for Paired Donation, a kidney exchange program for 50 transplant centers in 15 states, began using the matching algorithm in December. The Alliance director, Dr. Michael Rees of the University of Toledo Medical Center, said it improves on previous methods both by including three- and four-way exchanges and by factoring in so-called altruistic donors–kidney donors without a specified recipient.
    For instance, in a match run in early May, the algorithm identified four potential two-way exchanges, three three-way exchanges and one four-way exchange among about 100 donor-patient pairs and seven altruistic donors. Whether any of those transplants take place will depend on factors such as final compatibility testing, Rees said. With the same set of donor-patient pairs and without altruistic donors, the matching method previously used by the Alliance would have identified only one two-way exchange, he added.
    About 140 paired kidney donations have occurred in the United States since 1999, Rees said. These paired donations can happen when a friend or loved one is willing to donate a kidney to a patient but is found to be incompatible. When possible, a paired donation is then arranged, in which donor A is incompatible with recipient A, but can donate to recipient B, and donor B can donate to recipient A.
    Sandholm said the number of transplants could be increased by expanded use of three-way exchanges–donor A gives to recipient B, donor B gives to recipient C and donor C gives to recipient A–and four-way exchanges. Numbers could also be increased by enlarging the pool of donor-patient pairs, he added.
    Several regional exchanges are in operation and the possibility of a national exchange has been discussed. Rees predicted that in perhaps five years a national pool could include 3,000 donor-patient pairs and accumulate 1,000 to 1,500 pairs each year. Potentially, as many as 2,000 transplants could be performed from a pool of this size if three- and four-way exchanges are arranged, he said. But existing matching algorithms can arrange only two-way exchanges for such a large pool, and current algorithms capable of arranging three- and four-way exchanges can handle no more than 600 to 900 pairs.

    The paper (.pdf)
    Press release: Carnegie Mellon Scientists Devise Method To Increase Kidney Transplants …

    24524glau Oven Cleaner as Glaucoma Medicine?University of Central Florida scientists are reporting in the latest issue of the Journal of Physical Chemistry B that cerium oxide nanoparticles (nanoceria), a common ingredient in oven cleaners, not only inhibits carbonic anhydrase II enzyme, but also tends to have pretty good absorption rates across the cornea.
    Nanowerk reports:

    In a study scheduled for the June 28 issue of ACS’s Journal of Physical Chemistry B (“Surface-Derivatized Nanoceria with Human Carbonic Anhydrase II Inhibitors and Fluorophores: A Potential Drug Delivery Device”), a weekly publication, Sudipta Seal and Sanku Mallik describe early laboratory tests of cerium oxide nanoparticles (nanoceria) as drug delivery vehicles.
    Mallik and Seal note that barely 1-3 percent of existing glaucoma medicines penetrate into the eye, whereas experiments by other groups have shown high penetration rates for nanoparticles without undue patient discomfort from scratching. They combined nanoceria with a compound that blocks activity of an enzyme (hCAII) believed to play a central role in glaucoma. That disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks an enzyme that produces carbon dioxide.
    “These results are very promising, and more studies will likely evolve into an inhibition of hCAII in living cells and an effective treatment for glaucoma and other diseases,” their report states. “Furthermore, inhibitors for other pathogenic enzymes can be immobilized on the nanoceria and applied to the enzymes. The potential applications for functionalized cerium oxide nanoparticles seem limitless as a potential nontoxic drug delivery tool.”

    Nanowerk: Scientists eye nanoparticles as glaucoma treatment
    BBC: Oven cleaner offers glaucoma hope

    GI

    21524eso1 PillCam™ ESO 2
    PillCam™ ESO 2 is a new capsule endoscope from Israel’s Given Imaging Ltd., that just been 510(k)’ed by the FDA for imaging the esophagus. The company is reporting that U.S. marketing of the device will be done through InScope, a division of Ethicon Endo-Surgery, a Johnson & Johnson company.
    21524eso2 PillCam™ ESO 2

    The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-vitamin, which can be swallowed easily.
    Three sensor arrays are strategically placed on the patient’s chest and connected to a data recorder, worn on a belt around the waist.
    The patient swallows the capsule lying down, and is then raised in a series of inclinations over a total of 5 minutes. The PillCam™ ESO travels through the esophagus by normal peristaltic waves, flashing 14 times per second, each time capturing images of the inner lining of the esophagus.
    As it continues down the esophagus, the images captured may identify potential abnormalities, such as Esophagitis – which is inflammation of the lining of the esophagus often caused by Gastroesophageal Reflux Disease or GERD. Severity of symptoms is measured by a Grading system, and in severe cases, esophageal ulcers can appear.
    Images captured by the PillCam™ ESO may also identify symptoms of Barrett’s Esophagus, which occurs as a result of abnormal cell growth in the lower esophagus. Columnar cells, typically found in the lining of the stomach, replace the squamous cells in the lining of the esophagus, which can lead to a cancerous condition.
    21524eso3 PillCam™ ESO 2During this five-minute procedure, the PillCam™ ESO captures images, which are transmitted to the sensor arrays. These images then travel from the sensors, along the wires to the DataRecorder™. At this point, the patient is permitted to get up and walk or remain seated for an additional 15 minutes to ensure the capsule has traveled the entire length of the esophagus. After dropping into the stomach, the pill is later excreted naturally.
    Once all equipment is removed from the patient, the portable DataRecorder™ downloads the video images to a designated workstation, from which the physician views and assesses the results in order to recommend next steps in the patient’s treatment…
    PillCam ESO 2 features include:

  • Improved image quality
  • A 21% increase in the angle of view over PillCam ESO providing physicians more than a 100 percent increase in mucosal tissue coverage
  • Added Automatic Light Control (ALC) to provide optimal illumination for each image
  • Increased capture rate of 18 frames per second (fps), capturing 30% more images
  • Up to 30 minutes operating time
  • Same dimensions as PillCam ESO
  • Press release: Given Imaging Receives U.S. Marketing Clearance for PillCam(R) ESO 2 …
    J&J product page…
    Product page: PillCam™ ESO Capsule Endoscopy …
    Flashbacks: PillCam ; PillCam Colon; The Third Generation PillCam™ SB Launched; Enhanced Micron CMOS image sensor for PillCam; Given Imaging’s Agile™ Patency System; MagnaChip Image Sensor for "Pill" Camera
    (hat tip: Globes [online])

    6323wdr UniFit™ Abdominal Stent Graft
    LeMaitre Vascular, Inc., a Burlington, Massachusetts company, is trying to bring to the American market its endovascular UniFit™ Abdominal Stent Graft. The device has been sold in Europe for several years under the brand name EndoFit Aorto-Uni-Iliac Stent Graft. While endovascular AAA grafts are nothing new, this is another potentially exciting entrant in an increasingly competitive market.

    LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the first implant in the UNITE Clinical Trial of its UniFit(TM) Abdominal Stent Graft. The procedure was conducted at Emory University in Atlanta, Georgia.
    The UNITE pivotal study will evaluate the safety and effectiveness of the company’s UniFit Abdominal Stent Graft in the treatment of aorto, aorto-iliac, and/or iliac aneurysms. LeMaitre Vascular intends to enroll 90 patients in up to 14 centers in connection with the UNITE trial. These patients will be followed for at least one year prior to LeMaitre Vascular’s submission to the FDA of an application for premarket approval (PMA), which is prerequisite to commercial sale of the device in the United States. The primary effectiveness endpoint of the study is based on aneurysm exclusion as evaluated through one- year follow-up. The UNITE study compares the safety and efficacy of the UniFit Abdominal Stent Graft against open surgical abdominal aorta repair, because there are currently no aorto-uni-iliac endovascular stent grafts indicated for this use…
    The UniFit Abdominal Stent Graft is a single-bodied aorto-uni-iliac stent graft used to treat an aortic aneurysm-a weakening and ballooning of the aorta–through a minimally invasive endovascular procedure. The device’s encapsulated design minimizes the extent to which its stents contact the blood stream or the vessel wall. This design also allows a wider range of stent graft sizes, including tapered and custom grafts, to fit a wider range of patient anatomies than many competing products. The UniFit Abdominal Stent Graft is currently sold in the European Union and a small number of other foreign jurisdictions and is not available for sale in the United States.

    Press release: First Patient Implanted in UNITE Pivotal Study of LeMaitre Vascular’s Unifit Abdominal Stent Graft …
    Product page…